By Hamid Okhravi, MD
Alfred Abiouness Distinguished Professor of Geriatrics
Director, Goldrich Neurohealth Institute-Comprehensive Memory Center
Glennan Center for Geriatrics and Gerontology
In this talk, Dr. Okhravi delved into the significance of anti-amyloid monoclonal antibodies in the treatment of Alzheimer’s disease (AD), exploring the veracity behind their efficacy. The discussion centered around three key antibodies: Aducanumab, Lecanemab, and Donanemab, providing a comprehensive review of their respective phase 3 clinical trials. He navigated through the evidence, evaluating the promise and potential pitfalls of each antibody in combating AD. Additionally, he explored the current landscape and near-future trajectory of clinical trial designs in AD treatment, shedding light on emerging trends and methodologies.
Furthermore, the talk addressed the real-world impacts of disease-modifying therapies in AD, probing into the requirements, challenges, and implications for clinical practice. By unraveling the complexities surrounding anti-amyloid monoclonal antibodies and their role in AD treatment, this presentation aimed to provide clarity and insight into the evolving landscape of Alzheimer’s therapeutics.
